Brief: Paratek Pharmaceuticals Announces Modification Of Barda Contract To Advance The Development Of Nuzyra® (Omadacycline) For Post-Exposure Prophylaxis (Pep) And Treatment Of Pulmonary Anthrax
10/07/2023 13:03
Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES MODIFICATION OF BARDA
CONTRACT
TO ADVANCE THE DEVELOPMENT OF NUZYRA® (OMADACYCLINE) FOR
POST-EXPOSURE PROPHYLAXIS (PEP) AND TREATMENT OF PULMONARY
ANTHRAX
* PARATEK PHARMACEUTICALS INC- THIRD PROCUREMENT TO BE SPLIT
INTO
TWO PROCUREMENTS BASED ON ACHIEVEMENT OF SPECIFIC ANTHRAX
DEVELOPMENT MILESTONES
* PARATEK PHARMACEUTICALS INC- NEXT PROCUREMENT EXPECTED IN
EARLY
2024
* PARATEK - FIRST PROCUREMENT ON DELIVERY OF POSITIVE
TOP-LINE
DATA FROM DOSE-RANGING EFFICACY STUDY FOR PEP OF INHALATION
ANTHRAX IN NHPS
* PARATEK - SECOND PROCUREMENT WILL BE TRIGGERED BY BARDA'S
RECEIPT OF POSITIVE TOP-LINE DATA FROM A COMBINATION OF TWO
STUDIES
Source text for Eikon: ID:nGNXvlhqq
Further company coverage: PRTK.O
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million